Invivyd, Inc. announced the appointment of Sara Cotter to its board of directors. Ms. Cotter brings extensive leadership experience spanning healthcare investment management and drug development. Ms. Cotters comprehensive knowledge of the biopharmaceutical industry, pairing both operating and capital markets expertise, make her an excellent addition to our board of directors, said Dave Hering, Chief Executive Officer of Invivyd.

Her keen industry insights and impressive accomplishments in drug development and healthcare investing will be invaluable to Invivyd as we advance our lead candidate, VYD222, and our platform designed to generate a stream of optimized antibodies to protect vulnerable people from serious viral diseases. Ms. Cotter is currently the Portfolio Manager for the UBS Global Biotech Lux Fund as well as a Senior Investment Analyst on UBS Asset Managements Global Equity Team. Ms. Cotter rejoined UBS in 2022 after spending six years as Founder and Chief Executive Officer (CEO) of Levo Therapeutics, Inc., a venture-backed biotech company focused on developing impactful therapies for Prader-Willi syndrome.

During her tenure as Levos CEO, she oversaw all aspects of the company's late-stage advancement of intranasal carbetocin (LV-101), as well as early-stage pipeline research. Ms. Cotter started her investment career at UBS in 2007, and previously worked at Abbott Laboratories (now AbbVie Inc.) in pharmaceutical marketing, Northfield Laboratories in clinical development, and Deutsche Bank Alex Brown in investment banking. Ms. Cotter received an M.B. A from the Kellogg School of Management at Northwestern University and a B.S. from the University of Notre Dame.